Induced pluripotent stem cells (iPSCs) provide a potentially unlimited T cell source for CAR-T cell development and off-the-shelf products
M Sadeqi Nezhad, M Abdollahpour-Alitappeh… - Pharmaceutical …, 2021 - Springer
Chimeric antigen receptor T (CAR-T) cell therapy has been increasingly conducted for
cancer patients in clinical settings. Progress in this therapeutic approach is hampered by the …
cancer patients in clinical settings. Progress in this therapeutic approach is hampered by the …
Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products
MS Nezhad… - Pharmaceutical …, 2021 - pubmed.ncbi.nlm.nih.gov
Chimeric antigen receptor T (CAR-T) cell therapy has been increasingly conducted for
cancer patients in clinical settings. Progress in this therapeutic approach is hampered by the …
cancer patients in clinical settings. Progress in this therapeutic approach is hampered by the …
[PDF][PDF] Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products
MS Nezhad, M Abdollahpour-Alitappeh, B Rezaei… - researchgate.net
Chimeric antigen receptor T (CAR-T) cell therapy has been increasingly conducted for
cancer patients in clinical settings. Progress in this therapeutic approach is hampered by the …
cancer patients in clinical settings. Progress in this therapeutic approach is hampered by the …
Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products.
M Abdollahpour-Alitappeh, B Rezaei… - Pharmaceutical …, 2021 - europepmc.org
Chimeric antigen receptor T (CAR-T) cell therapy has been increasingly conducted for
cancer patients in clinical settings. Progress in this therapeutic approach is hampered by the …
cancer patients in clinical settings. Progress in this therapeutic approach is hampered by the …
Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products
SN Muhammad, AA Meghdad, R Behzad… - Pharmaceutical …, 2021 - search.proquest.com
Chimeric antigen receptor T (CAR-T) cell therapy has been increasingly conducted for
cancer patients in clinical settings. Progress in this therapeutic approach is hampered by the …
cancer patients in clinical settings. Progress in this therapeutic approach is hampered by the …
Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products.
M Sadeqi Nezhad… - Pharmaceutical …, 2021 - search.ebscohost.com
Chimeric antigen receptor T (CAR-T) cell therapy has been increasingly conducted for
cancer patients in clinical settings. Progress in this therapeutic approach is hampered by the …
cancer patients in clinical settings. Progress in this therapeutic approach is hampered by the …
[PDF][PDF] Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products
MS Nezhad, M Abdollahpour-Alitappeh, B Rezaei… - researchgate.net
Chimeric antigen receptor T (CAR-T) cell therapy has been increasingly conducted for
cancer patients in clinical settings. Progress in this therapeutic approach is hampered by the …
cancer patients in clinical settings. Progress in this therapeutic approach is hampered by the …